topotecan,ifosfamide
gsk
['sarcoma', 'reecur']
plenary abstract #2: dr. mccabe, reecur trial, topotecan/cyclophosphamide vs ifosfamide in refractory ewing sarcoma. median os 10.4m tc and 16.8m for ifos, hr 0.73. #asco22 
Gastrointestinal medical oncology, cancer of unknown primary, and value-based cancer care delivery. Tweets mine.